Metformin Treatment Sensitizes Human Laryngeal Cancer Cell Line Hep- 2 to 5-Fluorouracil

Author(s): Neslisah Barlak, Fatma Sanli, Ozel Capik, Elanur Tuysuz, Elanur Aydın Karatas, Hasan Turkez, Omer Faruk Karatas*.

Journal Name: Clinical Cancer Drugs

Volume 7 , Issue 1 , 2020

Become EABM
Become Reviewer

Graphical Abstract:


Abstract:

Background: Larynx cancer (LCa) is the most common head and neck cancer and accounts for 1-2.5% of all human cancers worldwide. Metformin, an oral anti-diabetic drug, has been recently shown to have anti-cancer activity in various cancer types, and there are several studies in the literature pointing to its potential to sensitize cancer cells to chemotherapeutic drugs.

Objective: This study was aimed at exploring the anti-cancer effects of metformin alone or in combination with 5-fluorouracil (5-FU) on Hep-2 cells.

Methods: The effects of metformin and/or 5-FU on the proliferative, clonogenic, and apoptotic potential of Hep-2 cells were evaluated with Cell Viability Detection Kit-8, soft agar assay and Annexin VFITC Apoptosis assay, respectively. Migratory and invasive potential of cells was tested using scratch, transwell migration and Matrigel invasion assays. Gene expression of cells exposed to metformin and/or 5-FU was profiled using RT2 mRNA PCR Array plates.

Results: Treatment of Hep-2 cells with metformin inhibited cell proliferation by inducing apoptosis, and suppressed cell migration. Besides, treatment of metformin along with 5-FU improved the antiproliferative and anti-migratory effects of 5-FU. However, unexpectedly, metformin was found to enhance cellular invasion and reverse the inhibitory effect of 5-FU on the invasive potential of Hep-2 cells.

Conclusion: Our findings suggest that metformin might be used as an adjuvant agent in the treatment of LCa. However, the potential of metformin to promote the invasion of cancer cells should not be neglected.

Keywords: Metformin, larynx cancer, Hep-2 cells, 5-Fluorouracil, chemotherapy, adjuvant.

[1]
Karatas OF, Suer I, Yuceturk B, et al. Identification of microRNA profile specific to cancer stem-like cells directly isolated from human larynx cancer specimens. BMC Cancer 2016; 16(1): 853.
[http://dx.doi.org/10.1186/s12885-016-2863-3] [PMID: 27816053]
[2]
Song FC, Yang Y, Liu JX. Expression and significances of MiRNA Let-7 and HMGA2 in laryngeal carcinoma. Eur Rev Med Pharmacol Sci 2016; 20(21): 4452-8.
[PMID: 27874955]
[3]
Luo J, Wu J, Li Z, et al. miR-375 suppresses IGF1R expression and contributes to inhibition of cell progression in laryngeal squamous cell carcinoma. BioMed Res Int 2014,. 2014374598
[http://dx.doi.org/10.1155/2014/374598] [PMID: 25184138]
[4]
Yilmaz SS, Guzel E, Karatas OF, Yilmaz M, Creighton CJ, Ozen M. MiR-221 as a pre and postoperative plasma biomarker for larynx cancer patients. Laryngoscope 2015; 125(12): E377-81.
[http://dx.doi.org/10.1002/lary.25332] [PMID: 25945817]
[5]
Yao XD, Li P, Wang JS. MicroRNA differential expression spectrum and microRNA-125a-5p inhibition of laryngeal cancer cell proliferation. Exp Ther Med 2017; 14(2): 1699-705.
[http://dx.doi.org/10.3892/etm.2017.4685] [PMID: 28810638]
[6]
Deng J, Wang Y, Lei J, Lei W, Xiong JP. Insights into the involvement of noncoding RNAs in 5-fluorouracil drug resistance. Tumour Biol 2017; 39(4) 1010428317697553
[http://dx.doi.org/10.1177/1010428317697553] [PMID: 28381160]
[7]
Chen Y, Sun L, Guo D, Wu Z, Chen W. Co-delivery of hypoxia inducible factor-1α small interfering RNA and 5-fluorouracil to overcome drug resistance in gastric cancer SGC-7901 cells. J Gene Med 2017; 19(12): e2998
[http://dx.doi.org/10.1002/jgm.2998] [PMID: 29106062]
[8]
Mohammed MO, Hussain KS, Haj NQ. Preparation and bioactivity assessment of chitosan-1-acetic acid-5-flurouracil conjugates as cancer prodrugs. Molecules 2017; 22(11): E1629
[http://dx.doi.org/10.3390/molecules22111629] [PMID: 29117097]
[9]
Milczarek M, Wiktorska K, Mielczarek L, et al. Autophagic cell death and premature senescence: New mechanism of 5-fluorouracil and sulforaphane synergistic anticancer effect in MDA-MB-231 triple negative breast cancer cell line. Food Chem Toxicol 2018; 111: 1-8.
[http://dx.doi.org/10.1016/j.fct.2017.10.056] [PMID: 29104175]
[10]
Thysiadis S, Katsamakas S, Dalezis P, Chatzisideri T, Trafalis D, Sarli V. Novel c(RGDyK)-based conjugates of POPAM and 5-fluorouracil for integrin-targeted cancer therapy. Future Med Chem 2017; 9(18): 2181-96.
[http://dx.doi.org/10.4155/fmc-2017-0139] [PMID: 29110537]
[11]
Dowling RJ, Goodwin PJ, Stambolic V. Understanding the benefit of metformin use in cancer treatment. BMC Med 2011; 9: 33.
[http://dx.doi.org/10.1186/1741-7015-9-33] [PMID: 21470407]
[12]
Rêgo DF, Pavan LM, Elias ST, De Luca Canto G, Guerra EN. Effects of metformin on head and neck cancer: A systematic review. Oral Oncol 2015; 51(5): 416-22.
[http://dx.doi.org/10.1016/j.oraloncology.2015.01.007] [PMID: 25636350]
[13]
Chang PH, Yeh KY, Wang CH, et al. Impact of metformin on patients with advanced head and neck cancer undergoing concurrent chemoradiotherapy. Head Neck 2017; 39(8): 1573-7.
[http://dx.doi.org/10.1002/hed.24793] [PMID: 28449193]
[14]
Ling S, Feng T, Ke Q, et al. Metformin inhibits proliferation and enhances chemosensitivity of intrahepatic cholangiocarcinoma cell lines. Oncol Rep 2014; 31(6): 2611-8.
[http://dx.doi.org/10.3892/or.2014.3151] [PMID: 24788596]
[15]
Wang LW, Li ZS, Zou DW, Jin ZD, Gao J, Xu GM. Metformin induces apoptosis of pancreatic cancer cells. World J Gastroenterol 2008; 14(47): 7192-8.
[http://dx.doi.org/10.3748/wjg.14.7192] [PMID: 19084933]
[16]
Shank JJ, Yang K, Ghannam J, et al. Metformin targets ovarian cancer stem cells in vitro and in vivo. Gynecol Oncol 2012; 127(2): 390-7.
[http://dx.doi.org/10.1016/j.ygyno.2012.07.115] [PMID: 22864111]
[17]
Sandulache VC, Hamblin JS, Skinner HD, Kubik MW, Myers JN, Zevallos JP. Association between metformin use and improved survival in patients with laryngeal squamous cell carcinoma. Head Neck 2014; 36(7): 1039-43.
[http://dx.doi.org/10.1002/hed.23409] [PMID: 23784886]
[18]
Zhou CY, Li XM, Shan S, Jia LF, Huang ZL. Metformin’s effect on 5-fluorouracil, cisplatin, paclitaxel in laryngocarcinoma Hep-2 cells. Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi 2017; 31(7): 524-8.
[PMID: 29871302]
[19]
Becker C, Jick SS, Meier CR, Bodmer M. Metformin and the risk of head and neck cancer: A case-control analysis. Diabetes Obes Metab 2014; 16(11): 1148-54.
[http://dx.doi.org/10.1111/dom.12351] [PMID: 25041125]
[20]
Zhang Y, Hu H. Long non-coding RNA CCAT1/miR-218/ZFX axis modulates the progression of laryngeal squamous cell cancer. Tumour Biol 2017; 39(6)1010428317699417
[http://dx.doi.org/10.1177/1010428317699417] [PMID: 28631575]
[21]
von Mässenhausen A, Sanders C, Thewes B, et al. MERTK as a novel therapeutic target in head and neck cancer. Oncotarget 2016; 7(22): 32678-94.
[http://dx.doi.org/10.18632/oncotarget.8724] [PMID: 27081701]
[22]
Rothman KJ, Cann CI, Flanders D, Fried MP. Epidemiology of laryngeal cancer. Epidemiol Rev 1980; 2: 195-209.
[http://dx.doi.org/10.1093/oxfordjournals.epirev.a036223] [PMID: 7000536]
[23]
Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013; 63(1): 11-30.
[http://dx.doi.org/10.3322/caac.21166] [PMID: 23335087]
[24]
Haigentz M Jr, Silver CE, Hartl DM, et al. Chemotherapy regimens and treatment protocols for laryngeal cancer. Expert Opin Pharmacother 2010; 11(8): 1305-16.
[http://dx.doi.org/10.1517/14656561003749256] [PMID: 20429666]
[25]
Adelstein DJ, Li Y, Adams GL, et al. An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. J Clin Oncol 2003; 21(1): 92-8.
[http://dx.doi.org/10.1200/JCO.2003.01.008] [PMID: 12506176]
[26]
Sanabria A, Chaves ALF, Kowalski LP, et al. Organ preservation with chemoradiation in advanced laryngeal cancer: The problem of generalizing results from randomized controlled trials. Auris Nasus Larynx 2017; 44(1): 18-25.
[http://dx.doi.org/10.1016/j.anl.2016.06.005] [PMID: 27397024]
[27]
Peng M, Darko KO, Tao T, et al. Combination of metformin with chemotherapeutic drugs via different molecular mechanisms. Cancer Treat Rev 2017; 54: 24-33.
[http://dx.doi.org/10.1016/j.ctrv.2017.01.005] [PMID: 28161619]
[28]
Longley DB, Harkin DP, Johnston PG. 5-fluorouracil: Mechanisms of action and clinical strategies. Nat Rev Cancer 2003; 3(5): 330-8.
[http://dx.doi.org/10.1038/nrc1074] [PMID: 12724731]
[29]
Mynhardt C, Damelin LH, Jivan R, et al. Metformin-induced alterations in nucleotide metabolism cause 5-fluorouracil resistance but gemcitabine susceptibility in oesophageal squamous cell carcinoma. J Cell Biochem 2018; 119(1): 1193-203.
[http://dx.doi.org/10.1002/jcb.26291] [PMID: 28722177]
[30]
Marin JJ, Sanchez de Medina F, Castaño B, et al. Chemoprevention, chemotherapy and chemoresistance in colorectal cancer. Drug Metab Rev 2012; 44(2): 148-72.
[http://dx.doi.org/10.3109/03602532.2011.638303] [PMID: 22497631]
[31]
Ward PS, Thompson CB. Metabolic reprogramming: A cancer hallmark even warburg did not anticipate. Cancer Cell 2012; 21(3): 297-308.
[http://dx.doi.org/10.1016/j.ccr.2012.02.014] [PMID: 22439925]
[32]
Quattrini I, Conti A, Pazzaglia L, et al. Metformin inhibits growth and sensitizes osteosarcoma cell lines to cisplatin through cell cycle modulation. Oncol Rep 2014; 31(1): 370-5.
[http://dx.doi.org/10.3892/or.2013.2862] [PMID: 24253938]
[33]
Gou S, Cui P, Li X, Shi P, Liu T, Wang C. Low concentrations of metformin selectively inhibit CD133+ cell proliferation in pancreatic cancer and have anticancer action. PLoS One 2013; 8(5): e63969
[http://dx.doi.org/10.1371/journal.pone.0063969] [PMID: 23667692]
[34]
Evans JM, Donnelly LA, Emslie-Smith AM, Alessi DR, Morris AD. Metformin and reduced risk of cancer in diabetic patients. BMJ 2005; 330(7503): 1304-5.
[http://dx.doi.org/10.1136/bmj.38415.708634.F7] [PMID: 15849206]
[35]
Landman GW, Kleefstra N, van Hateren KJ, Groenier KH, Gans RO, Bilo HJ. Metformin associated with lower cancer mortality in type 2 diabetes: ZODIAC-16. Diabetes Care 2010; 33(2): 322-6.
[http://dx.doi.org/10.2337/dc09-1380] [PMID: 19918015]
[36]
Singh S, Singh PP, Singh AG, Murad MH, Sanchez W. Anti-diabetic medications and the risk of hepatocellular cancer: a systematic review and meta-analysis. Am J Gastroenterol 2013; 108(6): 881-91.
[http://dx.doi.org/10.1038/ajg.2013.5] [PMID: 23381014]
[37]
Decensi A, Puntoni M, Goodwin P, et al. Metformin and cancer risk in diabetic patients: A systematic review and meta-analysis. Cancer Prev Res (Phila) 2010; 3(11): 1451-61.
[http://dx.doi.org/10.1158/1940-6207.CAPR-10-0157] [PMID: 20947488]
[38]
Rieken M, Xylinas E, Kluth L, et al. Association of diabetes mellitus and metformin use with oncological outcomes of patients with non-muscle-invasive bladder cancer. BJU Int 2013; 112(8): 1105-12.
[http://dx.doi.org/10.1111/bju.12448] [PMID: 24053906]
[39]
Rieken M, Xylinas E, Kluth L, et al. Effect of diabetes mellitus and metformin use on oncologic outcomes of patients treated with radical cystectomy for urothelial carcinoma. Urol Oncol 2014; 32(1): 49.
[http://dx.doi.org/10.1016/j.urolonc.2013.07.006] [PMID: 24140245]
[40]
Quimby AE, Lebo NL, Griffiths R, Hall S, Dimitroulakos J, Johnson-Obaseki S. Does metformin usage improve survival in head and neck squamous cell carcinoma? A population-based study. J Otolaryngol Head Neck Surg 2018; 47(1): 74.
[http://dx.doi.org/10.1186/s40463-018-0322-7] [PMID: 30514404]
[41]
Wang F, Ding X, Wang T, et al. Metformin inhibited esophageal squamous cell carcinoma proliferation in vitro and in vivo and enhanced the anti-cancer effect of cisplatin. PLoS One 2017; 12(4): e0174276
[http://dx.doi.org/10.1371/journal.pone.0174276] [PMID: 28406985]
[42]
Wu X, Yeerna H, Goto Y, et al. Metformin inhibits progression of head and neck squamous cell carcinoma by acting directly on carcinoma initiating cells. Cancer Res 2019; 79(17): 4360-70.
[http://dx.doi.org/10.1158/0008-5472.CAN-18-3525] [PMID: 31292160]
[43]
Esparza-López J, Alvarado-Muñoz JF, Escobar-Arriaga E, Ulloa-Aguirre A, de Jesús Ibarra-Sánchez M. Metformin reverses mesenchymal phenotype of primary breast cancer cells through STAT3/NF-κB pathways. BMC Cancer 2019; 19(1): 728.
[http://dx.doi.org/10.1186/s12885-019-5945-1] [PMID: 31337349]
[44]
Lee JE, Lim JH, Hong YK, Yang SH. High-dose metformin plus temozolomide shows increased anti-tumor effects in glioblastoma in vitro and in vivo compared with monotherapy. Cancer Res Treat 2018; 50(4): 1331-42.
[http://dx.doi.org/10.4143/crt.2017.466] [PMID: 29334602]
[45]
Kotsopoulos J, Singer C, Narod SA. Can we prevent BRCA1-associated breast cancer by RANKL inhibition? Breast Cancer Res Treat 2017; 161(1): 11-6.
[http://dx.doi.org/10.1007/s10549-016-4029-z] [PMID: 27783278]
[46]
Menendez JA, Cufí S, Oliveras-Ferraros C, et al. Metformin and the ATM DNA damage response (DDR): Accelerating the onset of stress-induced senescence to boost protection against cancer. Aging (Albany NY) 2011; 3(11): 1063-77.
[http://dx.doi.org/10.18632/aging.100407] [PMID: 22170748]
[47]
Gotlieb WH, Saumet J, Beauchamp MC, et al. In vitro metformin anti-neoplastic activity in epithelial ovarian cancer. Gynecol Oncol 2008; 110(2): 246-50.
[http://dx.doi.org/10.1016/j.ygyno.2008.04.008] [PMID: 18495226]
[48]
Jalving M, Gietema JA, Lefrandt JD, et al. Metformin: Taking away the candy for cancer? Eur J Cancer 2010; 46(13): 2369-80.
[http://dx.doi.org/10.1016/j.ejca.2010.06.012] [PMID: 20656475]
[49]
Rattan R, Graham RP, Maguire JL, Giri S, Shridhar V. Metformin suppresses ovarian cancer growth and metastasis with enhancement of cisplatin cytotoxicity in vivo. Neoplasia 2011; 13(5): 483-91.
[http://dx.doi.org/10.1593/neo.11148] [PMID: 21532889]
[50]
Yu T, Wang C, Yang J, Guo Y, Wu Y, Li X. Metformin inhibits SUV39H1-mediated migration of prostate cancer cells. Oncogenesis 2017; 6(5)e324
[http://dx.doi.org/10.1038/oncsis.2017.28] [PMID: 28459432]
[51]
Erices R, Cubillos S, Aravena R, et al. Diabetic concentrations of metformin inhibit platelet-mediated ovarian cancer cell progression. Oncotarget 2017; 8(13): 20865-80.
[http://dx.doi.org/10.18632/oncotarget.15348] [PMID: 28209916]
[52]
Kolli-Bouhafs K, Sick E, Noulet F, Gies JP, De Mey J, Rondé P. FAK competes for Src to promote migration against invasion in melanoma cells. Cell Death Dis 2014, .5e1379.
[http://dx.doi.org/10.1038/cddis.2014.329] [PMID: 25118939]
[53]
Lu Q, Lv M, Xu E, et al. Recombinant hirudin suppresses the viability, adhesion, migration and invasion of Hep-2 human laryngeal cancer cells. Oncol Rep 2015; 33(3): 1358-64.
[http://dx.doi.org/10.3892/or.2015.3717] [PMID: 25592110]
[54]
Jiralerspong S, Palla SL, Giordano SH, et al. Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer. J Clin Oncol 2009; 27(20): 3297-302.
[http://dx.doi.org/10.1200/JCO.2009.19.6410] [PMID: 19487376]
[55]
Niraula S, Dowling RJ, Ennis M, et al. Metformin in early breast cancer: A prospective window of opportunity neoadjuvant study. Breast Cancer Res Treat 2012; 135(3): 821-30.
[http://dx.doi.org/10.1007/s10549-012-2223-1] [PMID: 22933030]
[56]
Schuler KM, Rambally BS, DiFurio MJ, et al. Antiproliferative and metabolic effects of metformin in a preoperative window clinical trial for endometrial cancer. Cancer Med 2015; 4(2): 161-73.
[http://dx.doi.org/10.1002/cam4.353] [PMID: 25417601]


Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 7
ISSUE: 1
Year: 2020
Page: [16 - 24]
Pages: 9
DOI: 10.2174/2212697X06666190906165309

Article Metrics

PDF: 23
HTML: 1
EPUB: 1
PRC: 2